Prophylactic Role of Intra-Vitreal Bevacizumab(Avastin) in Diabetic Patients Under Going Phacoemulcification
Objectives: To study the effect of pre-operative intra-vitreal Avastin (bevacizumab) in diabetic patients undergoing phacoemulcification on central macular thickness and best corrected visual acuity.
Methods: A randomized controlled trial was conducted which included 42 patients (N=42). Group A and B had 21 patients each. Group A patients received injection Avastin (Bevacizumab) one week before phacoemulcification and Group B patient underwent phacoemulcification alone. Pre-operative best corrected visual acuity (BCVA) and central macular thickness (CMT) was recorded before giving intravitreal bevacizumab. Post-operative BCVA and CMT was noted 4 weeks after the surgery.
Results: The difference in final visual acuity between Group A and B was not statistically significant. Change
in CMT from pre-operative value was not significant in study population (p=0.364), but was statistically significant in both groups individually (p=0.029, 0.001 respectively).
Conclusion: Our study concludes that cataract surgery along with prophylacticintra-vitreal Avastin
(bevacizumab) may contribute in short term improvement of macular thickness, but does not have any
statistical significant effect on final BCVA.
Key Words: Bevacizumab (Avastin), Phacoemulcification, Best Corrected Visual Acuity, Centeral Macular Thickness (CMT)
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.